Allogeneic bone marrow transplantation using partially-matched related donors. NLM AIDSLINE Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Allogeneic bone marrow transplantation using partially-matched related donors.

Bone Marrow Transplant. 1987 Jun;2(1):27-32. Unique Identifier : AIDSLINE MED/89001392
Chan KW; Fryer CJ; Denegri JF; Buskard NA; Phillips GL; Leukemia and Bone Marrow Transplantation Program of British; Columbia, Vancouver General Hospital, Vancouver, Canada.

Abstract: Six patients with advanced leukemia and one with severe combined immunodeficiency syndrome received allogeneic bone marrow transplantation (BMT) from HLA haploidentical donors who were compatible for one or two loci on the non-shared chromosome. Methotrexate was used for prophylaxis against acute graft-versus-host disease (GVHD). All patients engrafted but developed moderate to severe acute GVHD, and three patients died. Two leukemic patients relapsed but two others survived and were free of disease 403 and 936 days post-transplant. BMT using related partially matched donors may result in durable engraftment and long-term survivors. The implications of using such donors in expanding the application of BMT are discussed.
Keywords: Bone Marrow/*TRANSPLANTATION *Bone Marrow Transplantation Graft vs Host Disease/COMPLICATIONS/THERAPY Histocompatibility Human HLA Antigens/IMMUNOLOGY Immunologic Deficiency Syndromes/*THERAPY Leukemia/*THERAPY Support, Non-U.S. Gov't Tissue Donors Virus Diseases/COMPLICATIONS JOURNAL ARTICLE

KWDbonemarrow/KWDtransplantationKWDbonemarrowtransplantationgraftvshostdisease/complications/therapyhistocompatibilityhumanhlaantigens/immunologyimmunologicdeficiencysyndromes/KWDtherapyleukemia/KWDtherapysupport,non-uKWDsKWDgov'ttissuedonorsvirusdiseases/complicationsjournalarticle
890130
M8910521

Copyright © 1989 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .